| Rheumatoid Arthritis
Rasuvo vs Vimovo
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Rasuvo vs Vimovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimovo has a higher rate of injection site reactions vs Rasuvo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimovo but not Rasuvo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rasuvo
Vimovo
At A Glance
SC injection
Once weekly
Folate analog metabolic inhibitor
Oral
Twice daily
NSAID + Proton Pump Inhibitor
Indications
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Psoriasis
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Juvenile arthritis
Dosing
Rheumatoid Arthritis 7.5 mg SC once weekly as starting dose; adjust gradually to achieve optimal response; doses greater than 20 mg/wk associated with increased serious toxicity; available doses 7.5-30 mg in 2.5 mg increments.
Juvenile polyarthritis 10 mg/m2 SC once weekly as starting dose; adjust gradually to achieve optimal response.
Psoriasis 10-25 mg SC once weekly as starting dose; adjust gradually; do not ordinarily exceed 30 mg/week; reduce to lowest effective dose and longest possible rest period once optimal response achieved.
Degenerative polyarthritis, Rheumatoid Arthritis, Ankylosing spondylitis Adults: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily, taken orally at least 30 minutes before meals; use lowest effective naproxen dose for shortest duration.
Juvenile arthritis Adolescents >=12 years and >50 kg: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily; 38 kg to <50 kg: one tablet (375 mg naproxen/20 mg esomeprazole) twice daily, taken at least 30 minutes before meals.
Contraindications
- Pregnancy
- Alcoholism, alcoholic liver disease, or other chronic liver disease
- Overt or laboratory evidence of immunodeficiency syndromes
- Preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia
- Known hypersensitivity to methotrexate
- Known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or any components of the drug product, including omeprazole
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
- Concomitant use of rilpivirine-containing products
Adverse Reactions
Most common (>=10%) Elevated liver function tests, nausea, vomiting
Serious Ulcerative stomatitis, leukopenia, hepatotoxicity, bone marrow suppression, interstitial pneumonitis, opportunistic infections, embryo-fetal toxicity, malignant lymphomas
Most common (>2%) Gastritis, diarrhea, upper respiratory tract infection, flatulence, headache, urinary tract infection, dysgeusia
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, fetal toxicity, hematologic toxicity
Postmarketing Gait disturbance, abdominal distension, hematochezia, joint swelling, muscle spasms, renal tubular necrosis, angioedema, aplastic anemia, hepatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, hypomagnesemia, cutaneous lupus erythematosus
Pharmacology
Methotrexate is a folate analog metabolic inhibitor that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication; in rheumatoid arthritis the mechanism may involve immune function modulation, and in psoriasis it exploits the differential in epithelial cell proliferation rates.
VIMOVO is a fixed-dose combination of naproxen, an NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis with analgesic, anti-inflammatory, and antipyretic effects, and esomeprazole magnesium, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in the gastric parietal cell to reduce naproxen-associated gastric ulcer risk.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rasuvo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Vimovo
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (1/12)
UnitedHealthcare
Rasuvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Vimovo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rasuvo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Vimovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rasuvo.
No savings programs available for Vimovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RasuvoView full Rasuvo profile
VimovoView full Vimovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.